Homopipramol: Difference between revisions
CSV import |
No edit summary |
||
| Line 22: | Line 22: | ||
[[Category:Anxiolytics]] | [[Category:Anxiolytics]] | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
<gallery> | <gallery> | ||
File:Homopipramol.svg|Homopipramol | File:Homopipramol.svg|Homopipramol | ||
</gallery> | </gallery> | ||
Latest revision as of 23:49, 16 March 2025
Homopipramol is a tricyclic antidepressant (TCA) that is used primarily in Europe for the treatment of depression and anxiety. It is less commonly used in other parts of the world due to the availability of newer, safer antidepressants.
Pharmacology[edit]
Homopipramol acts by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters that are involved in mood regulation. This increases the concentration of these neurotransmitters in the brain, which can help to alleviate symptoms of depression and anxiety.
Clinical Use[edit]
Homopipramol is used primarily for the treatment of depression, particularly when it is associated with anxiety. It can also be used for the treatment of insomnia and chronic pain conditions, although these uses are less common.
Side Effects[edit]
Like all TCAs, homopipramol can cause a number of side effects. These can include dry mouth, blurred vision, constipation, urinary retention, and weight gain. More serious side effects can include heart problems, seizures, and an increased risk of suicide.
History[edit]
Homopipramol was first synthesized in the 1960s and has been used in Europe for the treatment of depression and anxiety since that time. It is less commonly used in other parts of the world due to the availability of newer, safer antidepressants.
See Also[edit]
-
Homopipramol
